ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer? - OpacWWW

Szczegóły

Tytuł:: ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?
Autorzy:: Piltin MA; Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Boughey JC; Department of Surgery, Mayo Clinic, Rochester, MN, USA. .
Źródło:: Annals of surgical oncology [Ann Surg Oncol] 2021 Aug; Vol. 28 (8), pp. 4304-4305. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2005- : New York, NY : Springer
Original Publication: New York, NY : Raven Press, c1994-
MeSH Terms:: Breast Neoplasms*/genetics
Breast Neoplasms*/therapy
Carcinoma in Situ*
Carcinoma, Ductal, Breast*/genetics
Carcinoma, Ductal, Breast*/therapy
Carcinoma, Intraductal, Noninfiltrating*/genetics
Carcinoma, Intraductal, Noninfiltrating*/therapy
Female ; Genomics ; Humans
References:: Chabner E, Schnitt S, Harris J. Current management of patients with ductal carcinoma in situ. Oncologist. 1997;2(2):76–82. (PMID: 10.1634/theoncologist.2-2-76)
Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg. 2015;150(8):739–45. (PMID: 10.1001/jamasurg.2015.0876)
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC Cancer Staging Manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783–5. (PMID: 10.1245/s10434-018-6486-6)
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–98. (PMID: 10.1007/s10549-015-3464-6)
Manders JB, Kuerer HM, Smith BD, et al. Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3).660–8.
Piltin MA, Hoskin TL, Day CN, Shumway DA, Habermann EB, Davis J, Boughey JC. Use of the twelve-gene recurrence score for ductal carcinoma in situ and its influence on receipt of adjuvant radiation and hormonal therapy. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09517-z .
Entry Date(s):: Date Created: 20210202 Date Completed: 20210728 Latest Revision: 20210728
Update Code:: 20240104
DOI:: 10.1245/s10434-020-09573-5
PMID:: 33527230
: Czasopismo naukowe

Full Text Finder

Informacja

ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?